| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
A214370 Stock Overview
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩105,200.00 |
| 52 Week High | ₩133,000.00 |
| 52 Week Low | ₩50,400.00 |
| Beta | -0.016 |
| 1 Month Change | -6.82% |
| 3 Month Change | 69.95% |
| 1 Year Change | 66.46% |
| 3 Year Change | n/a |
| 5 Year Change | 53.35% |
| Change since IPO | -1.68% |
Recent News & Updates
Shareholder Returns
| A214370 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -5.5% | -5.1% | -3.0% |
| 1Y | 66.5% | -26.1% | -17.0% |
Return vs Industry: A214370 exceeded the KR Pharmaceuticals industry which returned -26.1% over the past year.
Return vs Market: A214370 exceeded the KR Market which returned -17% over the past year.
Price Volatility
| A214370 volatility | |
|---|---|
| A214370 Average Weekly Movement | 15.5% |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in KR Market | 10.5% |
| 10% least volatile stocks in KR Market | 3.2% |
Stable Share Price: A214370 is more volatile than 90% of KR stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: A214370's weekly volatility has increased from 8% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 157 | Yongji Chung | https://caregen.co.kr |
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR
Caregen Fundamentals Summary
| A214370 fundamental statistics | |
|---|---|
| Market Cap | ₩1.03t |
| Earnings (TTM) | ₩25.32b |
| Revenue (TTM) | ₩59.09b |
40.7x
P/E Ratio17.5x
P/S RatioIs A214370 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A214370 income statement (TTM) | |
|---|---|
| Revenue | ₩59.09b |
| Cost of Revenue | ₩13.64b |
| Gross Profit | ₩45.44b |
| Other Expenses | ₩20.13b |
| Earnings | ₩25.32b |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.58k |
| Gross Margin | 76.91% |
| Net Profit Margin | 42.85% |
| Debt/Equity Ratio | 0.0% |
How did A214370 perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield108%
Payout RatioValuation
Is Caregen undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
40.74x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: A214370 (₩105200) is trading above our estimate of fair value (₩67577.42)
Significantly Below Fair Value: A214370 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: A214370 is poor value based on its PE Ratio (40.7x) compared to the KR Pharmaceuticals industry average (26x).
PE vs Market: A214370 is poor value based on its PE Ratio (40.7x) compared to the KR market (14.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate A214370's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: A214370 is overvalued based on its PB Ratio (4.9x) compared to the KR Pharmaceuticals industry average (1.7x).
Future Growth
How is Caregen forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
18.7%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Caregen has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Caregen performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
17.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A214370 has high quality earnings.
Growing Profit Margin: A214370's current net profit margins (42.8%) are lower than last year (52.2%).
Past Earnings Growth Analysis
Earnings Trend: A214370's earnings have grown by 17.9% per year over the past 5 years.
Accelerating Growth: A214370's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A214370 had negative earnings growth (-19.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-15.5%).
Return on Equity
High ROE: A214370's Return on Equity (12%) is considered low.
Financial Health
How is Caregen's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: A214370's short term assets (₩149.3B) exceed its short term liabilities (₩9.8B).
Long Term Liabilities: A214370's short term assets (₩149.3B) exceed its long term liabilities (₩7.1B).
Debt to Equity History and Analysis
Debt Level: A214370 is debt free.
Reducing Debt: A214370 has not had any debt for past 5 years.
Debt Coverage: A214370 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: A214370 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Caregen current dividend yield, its reliability and sustainability?
Dividend Score
1/6Dividend Score 1/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
1.52%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: A214370's dividend (1.52%) is higher than the bottom 25% of dividend payers in the KR market (0.85%).
High Dividend: A214370's dividend (1.52%) is low compared to the top 25% of dividend payers in the KR market (2.75%).
Stability and Growth of Payments
Stable Dividend: A214370 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: A214370 has only been paying a dividend for 2 years, and since then payments have fallen.
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (108.4%), A214370's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (33.7%), A214370's dividend payments are well covered by cash flows.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Yongji Chung (51 yo)
no data
Tenure
Mr. Yongji Chung, Ph D., serves as the Chief Executive Officer and Chief Technology Officer at Caregen Co., Ltd.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Caregen Co., Ltd.'s employee growth, exchange listings and data sources
Key Information
- Name: Caregen Co., Ltd.
- Ticker: A214370
- Exchange: KOSDAQ
- Founded: 2001
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₩1.032t
- Shares outstanding: 9.81m
- Website: https://caregen.co.kr
Number of Employees
Location
- Caregen Co., Ltd.
- Caregen Building
- 46-38, LS-ro 91beon-gil
- Anyang-Si
- Gyeonggi-do
- 14119
- South Korea
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/10 00:00 |
| End of Day Share Price | 2022/05/10 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.